4 news items
Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual Meeting
NUVB
1 Jun 24
that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities
Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update
NUVB
14 May 24
are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward
Nuvation Bio Completes Acquisition of AnHeart Therapeutics
NUVB
10 Apr 24
for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements
Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer
NUVB
28 Mar 24
in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States
- Prev
- 1
- Next